CRISPR Therapeutics AG Executive Compensation Filing
Ticker: CRSP · Form: DEF 14A · Filed: Apr 16, 2025 · CIK: 1674416
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: CRSP
TL;DR
CRISPR exec comp details out - check equity awards for 2020-2024.
AI Summary
CRISPR Therapeutics AG filed a DEF 14A on April 16, 2025, detailing executive compensation. The filing includes information on equity awards granted in prior years and their fair value as of the vesting date, specifically for the fiscal years ending December 31, 2020, 2021, 2023, and 2024. It also reports changes in the fair value of outstanding equity awards granted in prior years.
Why It Matters
This filing provides transparency into how CRISPR Therapeutics AG compensates its executives, which can influence investor decisions regarding the company's governance and financial health.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present immediate financial risks.
Key Numbers
- 2020-2024 — Fiscal Years Covered (Executive compensation data for these years is detailed.)
Key Players & Entities
- CRISPR Therapeutics AG (company) — Filer
- 0000950170-25-054711 (filing_id) — Accession Number
- 20250416 (date) — Filing Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for an upcoming annual or special meeting of shareholders. It contains detailed information about matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
What specific compensation details are provided in this filing for CRISPR Therapeutics AG?
This filing provides details on equity awards granted in prior years, their fair value as of the vesting date, and changes in the fair value of outstanding equity awards for the fiscal years ending December 31, 2020, 2021, 2023, and 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 16, 2025.
What is the standard industrial classification for CRISPR Therapeutics AG?
The standard industrial classification for CRISPR Therapeutics AG is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is the fiscal year end for CRISPR Therapeutics AG?
The fiscal year end for CRISPR Therapeutics AG is December 31 (1231).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 16, 2025 regarding CRISPR Therapeutics AG (CRSP).